Higgins J R, Wambach G, Kem D C, Gomez-Sanchez C, Holland O B, Kaplan N M
J Lab Clin Med. 1977 Feb;89(2):250-6.
A previously unidentified mineralocorticoid, 16beta-hydroxydehydroepiandrosterone (16beta OH-DHEA) has recently been isolated from urine extracts of patients with low-renin hypertension and reported to possess one-fortieth the mineralocorticoid potency of aldosterone by bioassay. However, using a radioreceptor assay, we demonstrate the affinity of 16beta-OH-DHEA for renal 3H-aldosterone receptors to be only 0.011 per cent that of unlabeled aldosterone. 16beta-OH-DHEA therefore would not be expected to possess significant mineralocorticoid properties unless its mechanism of action involves binding to a unique class of renal receptors. Until these discrepancies between bioassayable mineralocorticoid activity and affinity for mineralocorticoid receptors can be resolved, the role of 16beta-OH-DHEA in the pathogenesis of low-renin hypertension remains speculative.
一种此前未被识别的盐皮质激素,16β-羟基脱氢表雄酮(16β OH-DHEA)最近已从低肾素性高血压患者的尿液提取物中分离出来,并且通过生物测定法报告其盐皮质激素效力仅为醛固酮的四十分之一。然而,使用放射受体测定法,我们证明16β-OH-DHEA对肾脏3H-醛固酮受体的亲和力仅为未标记醛固酮的0.011%。因此,除非其作用机制涉及与一类独特的肾脏受体结合,否则预计16β-OH-DHEA不会具有显著的盐皮质激素特性。在生物测定的盐皮质激素活性与对盐皮质激素受体的亲和力之间的这些差异得到解决之前,16β-OH-DHEA在低肾素性高血压发病机制中的作用仍具有推测性。